Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and technology. The founding partners Mariette van der Velden and Han de Groot both have extensive experience in investing, entrepreneurship and managing companies across the full life cycle from startup to (public) exit. The partners leverage their complementary skills and network for the success of their portfolio companies.
At Curie Capital we have the experience, risk appetite and funds to make investments in talented teams with exciting life science ideas. We take decisions quickly, and we spend our time supporting our partner-entrepreneurs. We provide access to our extensive network and we syndicate if needed with experienced co-investors. Curie Capital brings more to the table than capital; we actually help you to build your company.
We invest in seed and series A stage Biotechnology, Pharmaceutical and Medical Technology companies, typically focused on therapeutics, diagnostics or class IIb and III medical devices. From our main fund, we are compliant with the RVO seed capital regulations and therefore invest only in companies that have a Dutch headquarters and that have, so far, not raised more than €3 million in VC equity and convertible loan agreements.
“I am among those who think that science has great beauty.”
Han has a background of leading a consumer intelligence company called MetrixLab from start to public exit as founder, CEO and Board Member. Han founded MetrixLab in 1999 and expanded the company into multiple countries in- and outside of Europe. To speed up MetrixLab’s growth he successfully executed six acquisitions. In 2014 Han merged MetrixLab with MacroMill into a leading marketing tech company with +300M in annual revenue, 1800 employees and 30 offices worldwide. After the merger the companies continued under the ‘Macromill Group’ brand of which Han became global CEO until late 2015. Han remained Board Member until late 2016 and shareholder until the company went public on the Tokyo Stock Exchange in 2017. Han is also founder of VOC Capital Partners and Stadswaarde through which he invests in technology related companies and real estate respectively. Since 2017 Han is also an active investor in the field of Life Sciences and by co-founding Curie Capital in 2018 he looks to expand his activities in this fast developing field.
Mariette has an extensive background in the field of Life Sciences as she has 23 years of experience working for and with international companies developing and selling new medical technologies and medicines. During these years Mariette gained in depth experience and expertise in the field through a broad range of companies and products. From 2013 until 2018 Mariette was Senior Investment Manager Life Sciences & Health at the Brabantse Ontwikkelings Maatschappij (BOM). Here Mariette was responsible for the management of up to 13 portfolio companies where she represented the BOM as shareholder and, to a number of these companies, as Board Member. Before working as a Life Science investor, Mariette had 17 years of all round management and business development experience in biotech. This includes being highly involved in many innovative start-up ventures and the international launch of innovative products. In 2017 Mariette founded Curiant, through which she gives investment related consultancy to early stage companies and investors within the field of Life Sciences. By co-founding Curie Capital in 2018 Mariette uses her broad knowledge and experience in the Life Sciences field to invest in early stage start-ups.
Olivier Tak has a background in both Nanobiology and Medicine. Prior to co-initiating Curie Capital in 2018 and joining the first fund as an investment analyst, Olivier worked at De Groot Family Office as an analyst on their biotechnology portfolio. During his studies at the Delft University of Technology and Erasmus Medical Centre in Rotterdam, Olivier also completed internships at Medicxi, Kempen & Co and the Francis Crick Institute.
Thom has over 6,5 years of consultancy experiencein raising non-dilutive and dilutive funding for biopharmaceutical and medtech companies as advisor for Catalyze, Health-Holland and FFUND. In these years Thom was involved in raising over €85 million capital and has developed in-depth knowledge on a wide range of topics from ATMPand small molecule development to Medical Devices (class I, II and III) and in-vitro diagnostics. In addition, he was the CEO of 2ndB, an Organ-on-Chip start-up focused on creating neuron-based-networks using microfluidics for the pre-clinical prediction of efficacy for Parkinsons Disease therapeutics. Thom has a BSc and MSc in Science and Innovation Management at Utrecht University, where he graduated on a project with SkylineDx focused on a novel AI-based solution for the prediction of treatment outcome in Multiple Myeloma. Thom has completed his MBA with great distinction (magna cum laude) at the Vlerick Business School in Belgium.